

2021

英文論文

1. 2021 **Kudo M**\*, Morimoto M, Moriguchi M, Izumi N, Takayama T, Yoshiji H, Hino K, Oikawa T, Chiba T, Motomura K, Kato J, Yasuchika K, Ido A, Sato T, Ikawa Y, Ueshima K, Ikeda M, Okusaka T, Tamura K, Furuse J: A randomized, double-blind, placebo-controlled, phase III study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma. **Cancer Sci** 111:3759-3769, 2021(IF=6.716).
2. 2021 Hughes DM, Berhane S, de Groot CAE, Toyoda H, Tada T, Kumada T, Satomura S, Nishida N, **Kudo M**, Kimura T, Osaki Y, Kolamunage-Dona R, Salvador RA, Bird T, Garcia-Finana M, Johnson P: Serum levels of alpha fetoprotein increased more than 10 years before detection of hepatocellular carcinoma. **Clin Gastroenterol Hepatol** 19:162-170, 2021(IF=11.382).
3. 2021 **Kudo M**, Galle PR, Brandi G, Kang YK, Yen CJ, Finn RS, Llovet JM, Assenat E, Merle P, Chan SL, Palmer DH, Ikeda M, Yamashita T, Vogel A, Huang YH, Abada PB, Yoshikawa R, Shinozaki K, Wang C, Widau RC, Zhu AX: Effect of ramucirumab or best supportive care on ALBI grade in patients with advanced HCC: Results from REACH and REACH-2. **JHEP Reports** 3:100215, 2021 (<https://doi.org/10.1016/j.jhepr.2020.100215>)(IF=0.000).
4. 2021 Ikeda S, **Kudo M**, Izumi N, Kobayashi M, Azuma M, Meier G, Pan J, Ishii M, Kaneko S: Cost-effectiveness of lenvatinib in the treatment of patients with unresectable hepatocellular carcinomas in Japan: An analysis using data from Japanese patients in the REFLECT trial. **Value Health Reg Issues** 24:82-89, 2021(IF=1.174).
5. 2021 Chen M, Cao J, Hu J, Topatana W, Li S, Juengpanich S, Lin J, Tong C, Shen J, Zhang B, Wu J, Pocha C, **Kudo M**, Amedei A, Trevisani F, Sung PS, Zaydfudim VM, Kanda T, Cai X: Clinical-radiomic analysis for pretreatment prediction of objective response to first transarterial chemoembolization in hepatocellular carcinoma. **Liver Cancer** 10:38-51, 2021(IF=11.740).

2021

英文論文

6. 2021 **Kudo M**: Impact of multi-drug sequential therapy on survival in patients with unresectable hepatocellular carcinoma. **Liver Cancer** 10:1-9, 2021(IF=11.740).
7. 2021 Yoshida A, Uchima Y, Hosaka N, Minaga K, **Kudo M**: Transverse colonic volvulus due to mesenteric fibromatosis: a case report. **BMC Gastroenterology** 21:11, 2021.(IF=3.067)
8. 2021 Tsurusaki M, Sofue K, Hori M, Sasaki K, Ishii K, Murakami T, **Kudo M**: Dual-energy computed tomography of the liver: Uses in clinical practices and applications. **Diagnostics** 11:161, 2021(IF=3.706).
9. 2021 **Kudo M**, Tsuchiya K, Kato N, Hagihara A, Numata K, Aikata H, Inaba Y, Kondo S, Motomura K, Furuse J, Ikeda M, Morimoto M, Achira M, Kuroda S, Kimura A: Cabozantinib in Japanese patients with advanced hepatocellular carcinoma: A Phase II multicenter study. **J Gastroenterol** 56:181-190, 2021(IF=7.527).
10. 2021 Reig M, Galle PR, **Kudo M**, Finn R, Llovet JM, Metti AL, Schelman WR, Liang K, Wang C, Widau RC, Abada P, Zhu AX: Pattern of progression in advanced hepatocellular carcinoma treated with ramucirumab. **Liver Int** 41:598-607, 2021(IF=5.828).
11. 2021 **Kudo M**, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Tateishi R, Nakashima O, Murakami T, Matsuyama Y, Takahashi A, Miyata H, Kubo S: Report of the 21st nationwide follow-up survey of primary liver cancer in Japan (2010–2011). **Hepatol Res** 51:355-405, 2021(IF=4.288).
12. 2021 Aoki T, Kubota K, Kubo S, Eguchi S, Izumi N, Kokudo N, Sakamoto M, Shiina S, Takayama T, Nakashima O, Matsuyama Y, Murakami T, **Kudo M**: Analysis of patient outcome after non-curative resection for hepatocellular carcinoma using nationwide survey data in Japan. **World J Surg** 45:607-614, 2021(IF=3.352).

2021

英文論文

13. 2021 Minami Y, Minami T, Ueshima K, Yagyu Y, Tsurusaki M, Okada T, Hori M, **Kudo M**, Murakami T: Three-dimensional radiological assessment of ablative margins in hepatocellular carcinoma: Pilot study of overlay fused CT/MRI imaging with automatic registration. **Cancers** 13:1460, 2021(IF=6.639).
14. 2021 Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle P, Lencioni R, Greten TF, **Kudo M**, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR, for Panel of AASLD experts on Trial Design in HCC: Trial design and endpoints in hepatocellular carcinoma: AASLD consensus conference. **Hepatology** 73:158-191, 2021(IF=17.425).
15. 2021 Zhu AX, Finn RS, Kang YK, Yen CJ, Galle PR, Llovet JM, Assenat E, Brandi G, Motomura K, Ohno I, Daniele B, Vogel A, Yamashita T, Hsu CH, Gerken G, Bilbruck J, Hsu Y, Liang K, Widau RC, Wang C, Abada P, **Kudo M**: Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab. **Brit J Cancer** 124:1388-1397, 2021(IF=7.640).
16. 2021 Yoshikawa T, Watanabe T, Kamata K, Hara A, Minaga K, **Kudo M**: Intestinal dysbiosis and autoimmune pancreatitis. **Front Immunol** 12:621532, 2021(IF=7.561).
17. 2021 Kitano M, Yamashita Y, Kamata K, Ang TL, Imazu H, Ohno E, Hirooka Y, Fusaroli P, Seo DW, Napoleon B, Teoh AYB, Kim TH, Dietrich CF, Wang HP, **Kudo M**: The Asian Federation of Societies for Ultrasound in Medicine and Biology (AFSUMB) guidelines for contrast-enhanced endoscopic ultrasound. **Ultrasound Med Biol** 47:1433-1447, 2021(IF=2.998).
18. 2021 Minami Y, **Kudo M**: Image guidance in ablation for hepatocellular carcinoma: Contrast-enhanced ultrasound and fusion imaging. **Front Oncol** 11:593636, 2021(IF=6.244).

2021

英文論文

19. 2021 Sekai I, Watanabe T, Yoshikawa K, Takada R, Hara A, Yoshikawa T, Kamata K, Minaga K, **Kudo M**: A case with eosinophilic gastroenteritis exhibiting enhanced TNF- $\alpha$  and IL-6 responses. **Clin J Gastroenterol** 14:511-516, 2021(IF=1.206).
20. 2021 Ryoo BY, Merle P, Kulkarni AS, Cheng AL, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Daniele B, Norquist JM, Chen E, Siegel AB, Zhu AX, Finn RS, **Kudo M**\*: Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYNOTE-240. **Cancer** 127:865-874, 2021(IF=6.860).
21. 2021 Zhang T, Merle P, Wang H, Zhao H, **Kudo M**: Combination therapy for advanced hepatocellular carcinoma: do we see the light at the end of the tunnel? **Hepatobiliary Surg Nutr** 10:180-192, 2021(IF=7.293).
22. 2021 Hagiwara S, Watanabe T, **Kudo M**, Minaga K, Komeda Y, Kamata K, Kimura M, Hayashi H, Nakagawa K, Ueshima K, Minami Y, Aoki T, Takita M, Morita M, Chishina H, Ida H, Park AM, Nishida N: Clinicopathological analysis of hepatic immune-related adverse events in comparison with autoimmune hepatitis and graft-versus host disease. **Sci Rep** 11:9242, 2021(IF=4.379).
23. 2021 Yamazaki T, Takenaka M, Omoto S, Yoshikawa T, Ishikawa R, Okamoto A, Nakai A, Minaga K, Kamata K, Yamao K, Komeda Y, Sakurai T, Watanabe T, Nishida N, Kamei K, Matsumoto I, Takeyama Y, Chikugo T, Chiba Y, **Kudo M**: Should contrast-enhanced harmonic endoscopic ultrasound be incorporated into the international consensus guidelines to determine the appropriate treatment of intraductal papillary mucinous neoplasm? **J Clin Med** 10:1818, 2021(IF=4.241).
24. 2021 **Kudo M**\*: Combination immunotherapy with anti-VEGF/TKI for

2021

英文論文

- hepatocellular carcinoma: Present and future perspective. **Hepatobil Surg Nutr** 10:241-245, 2021(IF=7.293).
25. 2021 Kamata K, Kurita A, Yasukawa S, Chiba Y, Nebiki H, Asada M, Yasuda H, Shiomi H, Ogura T, Takaoka M, Hoki N, Ashida R, Shigekawa M, Yanagisawa A, **Kudo M**, Kitano M: Utility of a 20G needle with a core trap in EUS-guided fine-needle biopsy for gastric submucosal tumors: A multicentric prospective trial. **Endosc Ultrasound** 10:134-140, 2021(IF=5.628).
26. 2021 Hajiev S, Allara E, Motedayen-Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, **Kudo M**, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. **Brit J Cancer** 124:407-413, 2021(IF=7.640).
27. 2021 Hiraoka A, Kumada T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, **Kudo M**, On behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): What can be done to solve the unmet clinical need of hepatocellular carcinoma patients following lenvatinib failure? **Liver Cancer** 10:115-125, 2021(IF=11.740).
28. 2021 Hajiev S, Allara E, Motedayen-Aval L, Arizumi T, Bettinger D, Pirisi M, Rimassa L, Pressiani T, Personeni N, Giordano L, **Kudo M**, Thimme R, Park JW, Taddei TH, Kaplan DE, Ramaswami R, Pinato DJ, Sharma R: Correction: Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study. **Brit J Cancer** 124:1611, 2021(IF=7.640).

2021

英文論文

29. 2021 **Kudo M**: Sequential therapy for hepatocellular carcinoma after failure of atezolizumab plus bevacizumab combination therapy. **Liver Cancer** 10:85-93, 2021(IF=11.740).
30. 2021 Okusaka T, Ikeda K, **Kudo M**, Finn RS, Qin S, Han KH, Cheng AL, Piscaglia F, Kobayashi M, Sung M, Chen M, Wyrwicz L, Yoon JH, Ren Z, Mody K, Dutcus C, Tamai T, Ren M, Hayato S, Kumada H: Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT. **J Gastroenterol** 56:570-580, 2021(IF=7.527).
31. 2021 **Kudo M**, Ikeda M, Galle P, Yamashita T, Finn RS, Liang K, Wang C, Sakaguchi S, Abada P, Widau RC, Zhu AX: Ramucirumab in patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein: outcomes by treatment-emergent ascites. **Hepatol Res** 51:715-721, 2021(IF=4.288).
32. 2021 Takada R, Watanabe T, Sekai I, Yoshikawa K, Hara A, Otsuka Y, Yoshikawa T, Kamata K, Minaga K, Komeda Y, Hagiwara S, Chikugo T, Arai Y, Yamashita K, **Kudo M**: Concurrent Occurrence of Abdominal Double Expressor Lymphoma and Jejunum Follicular Lymphoma. **Front Oncol** 11:656219, 2021 (IF=6.244).
33. 2021 Takada R, Watanabe T, Hara A, Sekai I, Kurimoto M, Otsuka Y, Masuta Y, Yoshikawa T, Kamata K, Minaga K, **Kudo M**: NOD2 deficiency protects mice from the development of adoptive transfer colitis through the induction of regulatory T cells expressing forkhead box P3. **Biochem Bioph Res Commun** 568:55-61, 2021 (IF=3.575).
34. 2021 Hiraoka A, Kumada T, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ochi H, Yasuda S, Toyoda H, Ogawa C, Nishimura T, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Iijima H, Hiasa Y, **Kudo M**, On behalf of the Real-life Practice Experts for

2021

英文論文

- HCC (RELPEC) Study Group, and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience. **Cancer Rep**:e1464, 2021 (IF=0.000).
35. 2021 Hosono M, Takenaka M, Monzen H, Tamura M, **Kudo M**, Nishimura Y: Cumulative radiation doses from recurrent PET/CT examinations. **Brit J Radiol**:20210388, 2021 (IF =3.039).
36. 2021 Kawano K, Takenaka M, Kawano R, Kagoshige D, Kawase Y, Moriguchi T, Tanabe H, Katoh T, Nishi K, **Kudo M**: Efficacy of over-the-scope clip method as a novel hemostatic therapy for colonic diverticular bleeding. **J Clin Med** 10:2891, 2021 (IF =4.241).
37. 2021 Yoshida A, Takenaka M, Takashima K, Tanaka H, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Kamata K, Yamao K, Komeda Y, Nishida N, **Kudo M**: Usefulness of the novel snare-over-the-guidewire method for transpapillary plastic stent replacement (with video). **J Clin Med** 10:2858, 2021 (IF =4.241).
38. 2021 Komeda Y, Handa H, Matsui R, Yamamoto R, Sakurai T, Takenaka M, Nishida N, Watanabe T, **Kudo M**: Artificial intelligence-based endoscopic diagnosis of colorectal polyps using residual networks. **PLOS One** 16:e0253585, 2021 (IF=3.240).
39. 2021 Galle PR, Finn RS, Qin S, Ikeda M, Zhu AX, Kim TY, **Kudo M**, Breder V, Merle P, Kaseb A, Li D, Mulla S, Verret W, Xu DZ, Hernandez S, Ding B, Liu J, Huang C, Lim HY, Cheng AL, Ducreux M: Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomized, phase 3 trial. **Lancet Oncol** 22:991-1001, 2021 (IF=41.316).
40. 2021 Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydłowska

2021

英文論文

M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Youssuf S, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Heide D, Moncsek A, Stirm K, Kosla J, Prokosch S, Rothermel U, Dudek M, Kotsiliti E, O`Connor T, Leone V, Inverso D, Jansen J, Singh I, Yabal M, Castet F, Montironi C, Haber PK, Torrecilla S, Eichwald V, Jugold M, Ollinger R, Matter M, Terracciano L, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Rimassa L, Daly AK, Scheiner B, Romej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann A, Bueter M, Roessler F, Schmid J, Müllhaupt B, Kaeser R, Boettler T, Thimme R, Siebenhüner A, De Dosso S, Augustin HG, Schietinger A, Groth C, Umansky V, Billeter A, Müller-Stich B, Mallm JP, Mei H, Schulz A, Luedde T, Ringelhan M, Malek N, Spahn S, Bitzer M, Schirmacher P, Longerich T, Ranbari N, Dufour JF, Marron TU, Kaseb A, **Kudo M**, Huang YH, Teijeiro A, Djouder N, Weber A, Marche P, Pinato DJ, Decaens T, Jilkova ZM, Rad R, Mertens JC, Unger K, Meissner F, Roth S, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M: NASH limits anti-tumor surveillance in immunotherapy-treated HCC. **Nature** 592:450-456, 2021(IF=49.962).

41. 2021 Matsui S, Yamazaki T, Shiraishi O, **Kudo M**: Efficacy of endoscopic ultrasound-guided fine-needle aspiration for esophageal schwannoma. **Ann Gastroenterol** 34:597, 2021(IF=0.000).
42. 2021 Hara A, Watanabe T, Minaga K, Yoshikawa T, Kamata K, **Kudo M**: Biomarkers in autoimmune pancreatitis and immunoglobulin G4-related disease. **World J Gastroenterol** 27:2257-2269, 2021(IF=5.742).
43. 2021 **Kudo M**, Lim HY, Cheng AL, Chao Y, Yau T, Ogasawara S, Kurosaki M, Morimoto N, Ohkawa K, Yamashita T, Lee KH, Chen E, Siegel AB, Ryoo BY: Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of Asian



2021

英文論文

- Patients in the Phase 3 KEYNOTE-240 trial. **Liver Cancer** 10:275-284, 2021 (IF=11.740).
44. 2021 **Kudo M**\*, Motomura K, Wada Y, Inaba Y, Sakamoto Y, Kurosaki M, Umeyama Y, Kamei Y, Yoshimitsu J, Fujii Y, Aizawa M, Robbins PB, Furuse J: Avelumab in combination with axitinib as first-line treatment in patients with advanced hepatocellular carcinoma: results from the phase 1b VEGF Liver 100 trial. **Liver Cancer** 10:249-259, 2021 (IF=11.740).
45. 2021 **Kudo M**\*, Kawamura Y, Hasegawa K, Tateishi R, Kariyama K, Shiina S, Toyoda H, Imai Y, Hiraoka A, Ikeda M, Izumi N, Moriguchi M, Ogasawara S, Minami Y, Ueshima K, Murakami T, Miyayama S, Nakashima O, Yano H, Sakamoto M, Hatano E, Shimada M, Kokudo N, Mochida S, Takehara T, on behalf of the HCC Expert Panel of the Japan Society of Hepatology: Management of hepatocellular carcinoma in Japan: JSH consensus statements and recommendations 2020 update. **Liver Cancer** 10:181-223, 2021 (IF=11.740).
46. 2021 **Kudo M**\*: Surveillance, diagnosis, treatment outcomes of hepatocellular carcinoma in Japan: 2021 update. **Liver Cancer** 10:167-180a, 2021 (IF=11.740).
47. 2021 Vogel A, Qin S, **Kudo M**, Su Y, Hudgens S, Yamashita T, Yoon JH, Fartoux L, Simon K, López C, Sung M, Mody K, Otsuka T, Tamai T, Bennett L, Meier G, Breder V: Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. **Lancet Gastroenterol Hepatol** 6:649-658, 2021 (IF=18.486).
48. 2021 Hagiwara S, Nishida N, Ueshima K, Yoshida A, Minami Y, **Kudo M**: Comparison of efficacy and safety of the treatment of entecavir and switching entecavir to tenofovir alafenamide fumarate in chronic hepatitis B: Long term effects of the prospective study.

2021

英文論文

**Hepatol Res** 51:767-774, 2021 (IF=4.288).

49. 2021 **Kudo M**\*: Impaired response to immunotherapy in non-alcoholic steatohepatitis-related hepatocellular carcinoma? **Liver Cancer** 10:289-295, 2021 (IF=11.740).
50. 2021 Morita M, Nishida N, Sakai K, Aoki T, Chishina H, Takita M, Ida H, Hagiwara S, Minami Y, Ueshima K, Nishio K, Kobayashi Y, Kakimi K, **Kudo M**: Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody. **Liver Cancer** 10:380-393, 2021 (IF=11.740).
51. 2021 **Kudo M**\*: Lack of response to immunotherapy in non-alcoholic steatohepatitis related hepatocellular carcinoma. **Hepatobil Surg Nutr** 10:522-525, 2021 (IF=7.293).
52. 2021 Takashima K, Komeda Y, Sakurai T, Masaki S, Nagai T, Matsui S, Hagiwara S, Takenaka M, Nishida N, Kashida H, Watanabe T, **Kudo M**: Castor oil as booster for colon capsule endoscopy preparation reduction: A prospective pilot study and patient questionnaire. **World J Gastrointest Pharmacol Ther** 12:79-89, 2021 (IF=0.000).
53. 2021 Minaga K, Watanabe T, Hara A, Yoshikawa T, Kamata K, **Kudo M**: Plasmacytoid dendritic cells as a new therapeutic target for autoimmune pancreatitis and IgG4-related disease. **Front Immunol** 12:713779, 2021. doi: 10.3389/fimmu.2021.713779 (IF=7.561).
54. 2021 Honjo H, Watanabe T, Tomooka M, Matsubara T, Kono M, Sekai I, Hara A, Kurimoto M, Yoshikawa K, Masuda Y, Otsuka Y, Takada R, Yoshikawa T, Kamata K, Minaga K, Matsui S, Kimura M, **Kudo M**: Regulatory T cell-independent induction of remission in a patient with collagenous colitis. **Front Med** 8:678268, 2021. doi: 10.3389/fmed.2021.678268 (IF=5.091).

2021

英文論文

55. 2021 Kaibori M, Yoshii K, Kashiwabara K, Kokudo T, Hasegawa K, Izumi N, Murakami T, **Kudo M**, Shiina S, Sakamoto M, Nakashima O, Matsuyama Y, Eguchi S, Yamashita T, Takayama T, Kokudo N, Kubo S: Impact of hepatitis C virus on survival in patients undergoing resection of intrahepatic cholangiocarcinoma: report of a Japanese nationwide survey. **Hepatol Res** 51:890-901, 2021 (IF=4.288).
56. 2021 Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohma H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Ogawa C, Tamai T, Kakizaki S, Nagashima T, Ueno T, Tojima H, Takizawa D, Naganuma A, Okubo T, **Kudo M**: Therapeutic efficacy of lenvatinib as third line treatment following regorafenib for unresectable hepatocellular carcinoma progression. **Hepatol Res** 51:880-889, 2021 (IF=4.288).
57. 2021 Hiraoka A, Kumada T, Tada T, Tani J, Kariyama K, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Aoki T, anaka T, Ohama H, Nouse K, Tsutsui A, Nagano T, Itokawa N, Arai T, Okubo T, Imai M, Koizumi Y, Nakamura S, Joko K, Hiasa Y, **Kudo M**: Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: Multi-center retrospective study. **Sci Rep** 11:16663, 2021. doi.org/10.1038/s41598-021-96089-x (IF=4.379).
58. 2021 **Kudo M**, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaike M, Wisniewski T, Sangro B: CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis. **J Hepatol**

2021

英文論文

75:600-609, 2021 (IF=25.083).

59. 2021 Yamao K, Ogura T, Shiomi H, Eguchi T, Matsumoto H, Zhao L, Hashimoto H, Chiba Y, Takenaka M, Watanabe T, **Kudo M**, Sanuki T: Cross-wired Metal Stents for Endoscopic Bilateral Stent-in-Stent Deployment in Malignant Hilar Biliary Obstruction: A Multicenter, Single-arm, Prospective Study. **DEN Open** 2:e20, 2021. <https://doi.org/10.1002/deo2.20> (IF=0.000).
60. 2021 Takayama T, Yamazaki S, Matsuyama Y, Midorikawa Y, Shiina S, Izumi N, Hasegawa K, Kokudo N, Sakamoto M, Kubo S, **Kudo M**, Murakami T, Nakashima O, Liver Cancer Study Group of Japan: Prognostic grade for resecting hepatocellular carcinoma: a multicentre, retrospective study. **Bri J Surg** 108:412-418, 2021 (IF=6.939).
61. 2021 Takada R, Minaga K, Hara A, Otsuka Y, Omoto S, Kamata K, Yamao K, Takenaka M, Hagiwara S, Honjo H, Matsui S, Chikugo T, Watanabe T, **Kudo M**: Diagnostic value of EUS-guided fine-needle aspiration biopsy for gastric linitis plastica with negative endoscopic biopsy. **J Clin Med** 10:3716, 2021 (IF=4.241).
62. 2021 Minami Y, Morita M, Chishina H, Aoki T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, **Kudo M**: Can the entire ablative hyperechoic zone be regarded as a necrotic lesion after radiofrequency ablation of the liver? **Ultrasound Med Biol** 47:2930-2935, 2021 (IF=2.998).
63. 2021 Finn RS, **Kudo M**, Cheng AL, Wyrwicz L, Ngan RKC, Blanc JF, Baron AD, Vogel A, Ikeda M, Piscaglia F, Han KH, Qin S, Minoshima Y, Kanekiyo M, Ren M, Dairiki R, Tamai T, Dutcus CE, Ikezawa H, Funahashi Y, Evans TRJ: Pharmacodynamic biomarkers predictive of survival benefit with lenvatinib in unresectable hepatocellular carcinoma: From the Phase 3 REFLECT study. **Clin Cancer Res** 27:4848-4858, 2021 (IF=12.531).

2021

英文論文

64. 2021 Takenaka M, Hosono M, Hayashi S, Nishida T, **Kudo M**: The radiation doses and radiation protection on the endoscopic retrograde cholangiopancreatography procedures. **Brit J Radiol** 94:20210399, 2021. doi: 10.1259/bjr.20210399 (IF=3.039).
65. 2021 Kelley RK, Sangro B, Harris W, Ikeda M, Okusaka T, Kang YK, Qin S, David WM Tai, Lim HY, Yau T, Yong WP, Cheng AL, Gasbarrini A, Damian S, Bruix J, Borad M, Bendell J, Kim TY, Standifer N, He P, Parmd MM, Negro A, **Kudo M**, Abou-Alfa GK: Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: Randomized expansion of a Phase I/II study. **J Clin Oncol** 39:2991-3001, 2021 (IF=44.544).
66. 2021 Vogel A, Merle P, Verslype C, Finn RS, Zhu AX, Cheng AL, Chan SL, Yau T, Ryoo BY, Knox J, Daniele B, Qin S, Wei Z, Miteva Y, Malhotra U, Siegel AB, **Kudo M**: ALBI score and outcomes in patients with hepatocellular carcinoma: post hoc analysis of the randomized controlled trial KEYNOTE-240. **Ther Adv Med Oncol** 13: 17588359211039928, 2021 doi: 10.1177/17588359211039928. (IF=8.168).
67. 2021 Gandhi M, Ling WH, Chen CH, Lee JH, **Kudo M**, Chanwat R, Strasser SS, Xu Z, Lai SH, Chow PK: Impact of COVID-19 on hepatocellular carcinoma management: A multicountry and region study. **J Hepatocell Carcino** 8:1159-1167, 2021 (IF=5.828).
68. 2021 **Kudo M**\*: Adjuvant immunotherapy after curative treatment for hepatocellular carcinoma. **Liver Cancer** 10:399-403, 2021 (IF=11.740).
69. 2021 Vogel A, Frenette C, Sung M, Daniele B, Baron A, Chan SL, Blanc JF, Tamai T, Ren M, Lim HJ, Palmer DH, Takami Y, **Kudo M**: Baseline liver function and subsequent outcomes in the phase 3 REFLECT study of patients with unresectable hepatocellular

2021

英文論文

- carcinoma. **Liver Cancer** 10:510-521, 2021 (IF=11.740).
70. 2021 Yamao K, Tsurusaki M, Takashima K, Tanaka H, Yoshida A, Okamoto A, Yamazaki T, Omoto S, Kamata K, Minaga K, Takenaka M, Chikugo T, Chiba Y, Watanabe T, **Kudo M**: Analysis of progression time in pancreatic cancer including carcinoma in situ based on magnetic resonance cholangiopancreatography findings. **Diagnostics** 11:1858, 2021. doi: 10.3390/diagnostics11101858. (IF=3.706)
71. 2021 Minaga K, Kitano M, Nakai A, Omoto S, Kamata K, Yamao K, Takenaka M, Tsurusaki M, Chikugo T, Matsumoto I, Chiba Y, Watanabe T, **Kudo M**: Improved detection of liver metastasis using Kupffer-phase imaging in contrast-enhanced harmonic EUS in patients with pancreatic cancer (with video). **Gastrointest Endosc** 93:773-774, 2021 (IF=9.427).
72. 2021 Hagiwara S, Nishida N, **Kudo M**: Improved tumor response to lenvatinib re-treatment after failure of immune checkpoint inhibitors in a patient with advanced hepatocellular carcinoma. **Liver Cancer** 10:525-538, 2021 (IF=11.740).
73. 2021 **Kudo M**, Finn R, Morimoto M, Rau KM, Ikeda M, Yen CJ, Galle PR, Llovet J, Daniele B, Lim HY, McIlwain DW, Yoshikawa R, Nakamura K, Liang K, Wang C, Abada P, Widau RC, Zhu AX: Ramucirumab for patients with intermediate-stage hepatocellular carcinoma and elevated alpha-fetoprotein: pooled results from two phase 3 studies (REACH and REACH-2). **Liver Cancer** 10:451-460, 2021 (IF=11.740).
74. 2021 Yamashita Y, Shimokawa T, Ashida R, Dietrich CF, D'Onofrio M, Hirooka Y, **Kudo M**, Mori H, Sofuni A, Kitano M: Value of low-mechanical-index contrast-enhanced transabdominal ultrasound for diagnosis of pancreatic cancer: A meta-analysis. **Ultrasound Med Biol** 47:3315-3322, 2021 (IF=2.998).

2021

英文論文

75. 2021 Galle PR, **Kudo M**, Llovet JM, Finn RS, Karwal M, Pezet D, Kim TY, Yang TS, Lonardi S, Tomasek J, Phelip JM, Touchefeu Y, Koh SJ, Stirnimann G, Liang K, Ogburn KD, Wang C, Abada P, Widau RC, Zhu AX: Ramucirumab in patients with previously treated advanced hepatocellular carcinoma: Impact of liver disease etiology. **Liver Int** 41:2759-2767, 2021 (IF=5.828).
76. 2021 Kurimoto M, Watanabe T, Kamata K, Minaga K, **Kudo M**: IL-33 as a critical cytokine for inflammation and fibrosis in inflammatory bowel diseases and pancreatitis. **Front Physiol** 12:781012, 2021. doi: 10.3389/fphys.2021.781012. (IF=4.566)
77. 2021 **Kudo M**\*: Changing the treatment paradigm for hepatocellular carcinoma using atezolizumab plus bevacizumab combination therapy. **Cancers** 13:5475, 2021. doi: 10.3390/cancers13215475. (IF=6.639)
78. 2021 Hagiwara S, Nishida N, Ueshima K, Minami Y, Komeda Y, Aoki T, Takita M, Morita M, Chishina H, Yoshida A, Ida H, **Kudo M**: Accumulation of genetic and epigenetic alterations in the background liver and emergence of hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. **Cells** 10:3257, 2021. doi: 10.3390/cells10113257 (IF=6.600)
79. 2021 Sakai K, Sakurai T, De Velasco MA, Nagai T, Chikugo T, Ueshima K, Kura Y, Takahama T, Hayashi H, Nakagawa K, **Kudo M**, Nishio K: Intestinal microbiota and gene expression reveal similarity and dissimilarity between Immune-mediated colitis and ulcerative colitis. **Front Oncol** 11:763468, 2021. doi: 10.3389/fonc.2021.763468 (IF=6.244).
80. 2021 **Kudo M**\*: A novel treatment strategy for patients with Intermediate-stage HCC who are not suitable for TACE: Upfront systemic therapy followed by curative conversion. **Liver Cancer** 10:539-544, 2021 (IF=11.740).

2021

英文論文

81. 2021 Fessas P, Naeem M, Pinter M, Marron TU, Szafron D, Balcar L, Scheiner B, Saeed A, Jun T, Dharmapuri S, Gampa A, Wang Y, Khan U, Muzaffar M, Navaid M, Lee PC, Bulumulle A, Yu B, Paul S, Nimkar N, Bettinger D, Hildebrand H, Yehia M, Pressiani T, Personeni N, Nishida N, **Kudo M**, Kaseb A, Huang YH, Ang C, Pillai A, Rimassa L, Naqash AR, Sharon E, Cortellijni A, Pinato DJ: Early antibiotic exposure is not detrimental to therapeutic effect from immunotherapy in hepatocellular carcinoma. **Liver Cancer** 10:583-592, 2021 (IF=11.740).
82. 2021 Aoki T, Nishida N, Ueshima K, Morita M, Chishina H, Takita M, Hagiwara S, Ida H, Minami Y, Yamada A, Sofue K, Tsurusaki M, **Kudo M**: Higher enhancement intrahepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI as a poor responsive marker of anti-PD-1 / PD-L1 monotherapy for unresectable hepatocellular carcinoma. **Liver Cancer** 10:615-628, 2021 (IF=11.740).
83. 2021 Hiraoka A, Kumada T, Kariyama K, Tada T, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Arai T, Imai M, Koizumi Y, Nakamura S, Michitaka K, Hiasa Y, **Kudo M**, on behalf of the Real-life Practice Experts for HCC (RELPEC) Study Group and HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan): Clinical importance of muscle volume in lenvatinib for hepatocellular carcinoma: analysis adjusted with inverse probability weighting. **J Gastroenterol Hepatol** 36:1812-1819, 2021.
84. 2021 Komeda Y, Watanabe T, **Kudo M**: Requirement of additional surgery after non-curative endoscopic submucosal dissection for early colorectal cancer. **J Invest Surg** 34:895-896, 2021 (IF=2.533).



2021

英文論文

85. 2021 Ishikawa R, Kamata K, Hara A, Tanaka H, Okamoto A, Yamazaki T, Nakai A, Omoto S, Minaga K, Yamao K, Takenaka M, Minami Y, Watanabe T, Chiba Y, Chikugo T, Matsumoto I, Takeyama Y, **Kudo M**: Utility of contrast-enhanced harmonic endoscopic ultrasonography for predicting the prognosis of pancreatic neuroendocrine neoplasms. **Digest Endosc**33:829-839, 2021 (IF=7.559).
86. 2021 Sekai I, Hagiwara S, Watanabe T, **Kudo M**: A case with hepatic immune-related adverse events caused by nivolumab exhibiting impaired accumulation of regulatory T cells. **Clin J Gastroenterol** 14:1191-1196, 2021 (IF=1.206).
87. 2021 Takenaka M, **Kudo M**: Endoscopic papillotomy and papiloplasty: Effects on sphincter of Oddi functionality and outcomes. **Dig Endosc** 33:924-926, 2021 (IF=7.559).
88. 2021 Takenaka M, **Kudo M**: Current status of endoscopic re-intervention for hilar malignant biliary obstruction. **Digest Endosc** 33:746-748, 2021 (IF=7.559).
89. 2021 Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, Ju SH, Kartalis N, **Kudo M**, Lee JM, Murakami T, Seidensticker M, SirlinCB, Tan CH, Wang J, Yoon JH, Zeng M, Zhou J, Taouli B: Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. **Eur Radiol** 31:5615-5628, 2021 (IF=5.315).
90. 2021 Minaga K, Watanabe T, **Kudo M**: Probiotic-Derived Polyphosphate Prevents Pancreatitis. **Dig Dis Sci** 66:3665-3667, 2021 (IF=3.199).
91. 2021 Kawaguchi Y, Hasegawa K, Hagiwara Y, De Bellis M, Famularo S, Panettieri E, Matsuyama Y, Tateishi R, Ichikawa T, Kokudo T, Izumi N, Kubo S, Sakamoto M, Shiina S, Takayama T, Nakashima O,

2021

英文論文

- Murakami T, Vauthey JN, Giulante F, De Carlis L, Romano F, Ruzzenente A, Guglielmi A, **Kudo M**, Kokudo N: Effect of diameter and number of hepatocellular carcinomas on survival after resection, trans-arterial chemoembolization, and ablation. **Am J Gastroenterol** 116:1698-1708, 2021 (IF=10.864).
92. 2021 Muhammed A, Fulgenzi CAM, Pinter M, Balcar L, Marron TU, Jun T, Dharmapuri S, Ang C, Saeed A, Hildebrand H, Navaid M, Naqash AR, Gampa A, Vincenzi B, Silletta M, Pillai A, Wang Y, Muzaffar M, Khan U, Huang YH, Bettinger D, Abugabal YI, Kaseb A, Pressiani T, Personeni N, Rimassa L, Nishida N, Tommaso LD, **Kudo M**, Vogel A, Mauri FA, Cortellini A, Sharma R, D'Alessio A, Pinato DJ: The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma. **Cancers** 14:186, 2021. doi: 10.3390/cancers14010186 (IF=3.067).
93. 2021 Suzuki F, Suzuki Y, Karino Y, Tanaka Y, Kurosaki M, Yatsunami H, Atarashi T, Atsukawa M, Watanabe T, Enomoto M, **Kudo M**, Maeda N, Kohno H, Joko K, Michitaka K, Miki K, Takahashi K, Ide T, Fujiyama S, Kohno T, Itoh H, Tsukamoto S, Suzuki Y, Kawano Y, Sugiura W, Kumada H: Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: Phase 4, prospective study. **BMC Gastroenterol** 21:489, 2021. doi: 10.1186/s12876-021-02008-9 (IF=3.067).